kai-1678
Peptideexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2008 (NCT01015235)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Protein kinase C epsilonINHIBITOR
Protein kinase C epsilon inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297775 ↗
Also known as
- kai-1678
- kai-1678
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01106716 | Phase 2 | Mar 1, 2009 | KAI Pharmaceuticals, Trident Clinical Research Pty Ltd |
| NCT01135108 | Phase 2 | Mar 1, 2009 | KAI Pharmaceuticals, Trident Clinical Research Pty Ltd |
| NCT01015235 | Phase 2 | Dec 1, 2008 | KAI Pharmaceuticals, Trident Clinical Research Pty Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| KAI Pharmaceuticals | For profit | 3 | 3 | 1 | 2008 |
| Trident Clinical Research Pty Ltd | For profit | 3 | 0 | 1 | 2008 |
2 organizations
Page 1 / 1